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ABSTRACT 
Background: Malnutrition may be common in heart failure (HF) and associated with 
adverse outcomes but few data exist.  
Objectives: To report the prevalence, clinical associations and prognostic consequences of 
malnutrition in out-patients with HF. 
Methods: We applied the geriatric nutritional risk index (GNRI), controlling nutritional 
status (CONUT) score and prognostic nutritional index (PNI), to consecutive patients referred 
with suspected HF to a clinic serving a local population (n≈550,000). 
Results: Of 4,021 patients enrolled, HF was confirmed in 3,386 (61% men, median age 75 
(interquartile range (IQR): 67-81) years, median NTproBNP 1,103 (IQR: 415-2,631) ng/L). 
Left ventricular ejection fraction (LVEF) was <40% in 35%. Using scores for GNRI ≤91, 
CONUT >4 and PNI ≤38, 6.7%, 10.0% and 7.5% patients were moderately or severely 
malnourished; 57% were at least mildly malnourished by at least one score. Worse scores 
were most strongly related to older age, lower body mass index (BMI), worse symptoms and 
renal function, atrial fibrillation, anaemia, and reduced mobility. 
During a median follow-up of 1,573 days (interquartile range: 702-2,799 days), 1,723 (51%) 
patients died. For patients moderately or severely malnourished, one year mortality was 28% 
for CONUT, 41% for GNRI, and 36% for PNI, compared to 9% for those with mild 
malnutrition or normal nutritional status.  
A model including only age, urea and logNTproBNP, predicted one year survival (c-statistic 
0.719) and was slightly improved by adding nutritional indices (up to 0.724; P<0.001) but not 
BMI. 
Conclusion: Malnutrition is common amongst out-patients with HF and is strongly related to 
increased mortality.  
(250 words) 
 
Key words: Heart failure, malnutrition, CONUT, GNRI, PNI, BMI, mortality. 
 
 
Abbreviations: HF= heart failure, CONUT = COntrolling NUTritional Status index, PNI= 
prognostic nutritional index, GNRI = geriatric nutritional risk index, LVEF= left ventricular 
ejection fraction, NTproBNP= N-terminal pro-B-type natriuretic peptide, HeFREF= heart 
failure with reduced ejection fraction, HeFNEF= heart failure with normal ejection fraction. 
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Introduction 
Although often ignored, malnutrition is common in patients with chronic heart failure (HF)
1 
 
and associated with a high mortality.
2-3  
Severe HF may lead to loss of appetite, 
malabsorption and a catabolic state leading to malnutrition.
1
 Malnutrition may also be a 
driver of disease progression as part of a vicious cycle associated with cytokine activation, 
autonomic dysfunction and cachexia.
4
  
 
Screening patients with HF for malnutrition might identify patients at high risk of adverse 
outcomes who might benefit from tailored treatments or interventions to prevent deterioration 
in HF and improve prognosis.
5 
There are many screening tools for malnutrition but no 
consensus on which to use for patients with HF.
6-8 
Amongst malnutrition scores, 
the COntrolling NUTritional Status index (CONUT), the prognostic nutritional index 
(PNI)
Error! Bookmark not defined.
 and the geriatric nutritional risk index (GNRI) have been studied 
in HF.
9   
The prevalence of malnutrition varies depending on the screening tool used and has 
been reported to be as high as 69% in some HF populations.
9
 Malnutrition determined by any 
of these scoring methods is an independent predictor of worsening HF and/or mortality.
9
 
However, the studies conducted so far have been small and may not have been 
epidemiologically representative of the general population with HF. 
 
Accordingly, we investigated the prevalence and prognostic importance of malnutrition using 
three different scoring systems in a large, well-characterised cohort of ambulatory patients 
with HF.   
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Methods 
Study population 
Consecutive consenting patients referred to a community HF clinic between 2000 and 2016 
with suspected HF were enrolled. HF was defined as the presence of symptoms or signs of 
HF and evidence of cardiac dysfunction; either a left ventricular ejection fraction (LVEF) 
<40% or a raised plasma concentration of N-terminal pro-B-type natriuretic peptide 
(NTproBNP) (>125ng/L).
10 
We excluded patients from this analysis if they had no 
measurement of height, weight or NTproBNP recorded and six patients with a diagnosis of 
chronic lymphocytic leukaemia (Online figure 1).  
 
Patients with HF were phenotyped as reduced ejection fraction (HeFREF: LVEF <40%, or at 
least moderate left ventricular systolic dysfunction by visual inspection on echocardiography 
if LVEF was not available); or normal ejection fraction (HeFNEF: LVEF >40%; or better 
than, or equal to, mild-moderate left ventricular systolic dysfunction by visual inspection on 
echocardiography if LVEF was not available and NTproBNP >125ng/L).
10
 Patients with an 
LVEF >40% and NTproBNP ≤125ng/L were considered not to have HF. Patients with HF 
were stratified by plasma NTproBNP concentration: ≤400, 401-1000, 1001-2000, 2001-4000 
and >4000 ng/L.  
 
A medical history and findings on physical examination were recorded. Ischaemic heart 
disease (IHD) was defined as any previous medical history of acute coronary syndrome 
(ACS), percutaneous coronary intervention or coronary artery bypass surgery, or diagnosis of 
myocardial ischemia based on invasive or non-invasive diagnostic tests. Cerebrovascular 
disease (CVD) was defined as any previous history of stroke or transient ischaemic attack 
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(TIA). Peripheral vascular disease (PVD) was defined as evidence of extra-cardiac arterial 
disease at ultrasound, such as those of the lower limbs and abdominal aorta. Chronic 
obstructive pulmonary disease (COPD), hypertension (HTN) and active cancer were defined 
as a clinical history of the diagnoses recorded in patient’s notes. Significantly deranged liver 
function test was defined as serum alanine aminotransferase (ALT) > 50% upper limit of 
normal.  
 
Blood was taken for standard haematology and biochemistry profiles and NTproBNP. 
Patients had an electrocardiogram and echocardiogram done by an experienced sonographer 
using a Vivid 5, 7 or 9 Scanner (GE, Fairfield, Connecticut, USA). All patients had left 
ventricular systolic function evaluated by visual assessment recorded (ranging from normal to 
severely impaired), whilst LVEF was calculated using Simpson’s method. Patients were 
weighed in their casual wear without shoes. Body mass index (BMI) was calculated using the 
formula: BMI = weight in kilograms / (height in meters) squared, and patients were classified 
into 5 BMI (kg/m
2
) categories: underweight (BMI<18.5), normal (BMI = 18.5-24.9), 
overweight (BMI = 25.0-29.9), obese (BMI = 30-39.9) and morbidly obese (BMI ≥40).11  
 
The study conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent for their 
data to be used for research. 
 
Malnutrition screening tools 
Patients were screened for malnutrition using three indices (Online table 1). 
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a) The geriatric nutritional risk index (GNRI) is calculated using the formula: 1.489 x serum 
albumin (g/L) + 41.7 x (body weight in kilograms / ideal body weight).
7
 We calculated the 
ideal body weight using the formula: 22 x square of height in meters.
12 
A score of >98 is 
considered normal; scores of 92-98, 82-91 and <82 reflect mild, moderate and severe 
malnutrition, respectively.  
b) The controlling nutritional status score (CONUT score) was developed by Ulibarri and 
colleagues in 2005 as a screening tool for the nutritional status of hospitalised patients.
6
 The 
CONUT score takes into account serum albumin, cholesterol and total lymphocyte count. A 
score of 0-1 is considered normal; scores of 2-4, 5-8 and 9-12 reflect mild, moderate and 
severe malnutrition, respectively.  
c) The prognostic nutritional index (PNI) is calculated using the formula: 10 x serum albumin 
(g/dL) + 0.005 x total lymphocyte count (mm
3
).
8
 A score of >38 is considered normal; scores 
of 35-38 and <35 reflect moderate and severe malnutrition, respectively. Note there is no 
‘mild’ category for PNI. 
 
End points and follow-up 
Patients were followed up until 19
th
 July 2016. The primary endpoint was all-cause mortality. 
Our hospital is the only one in the region offering acute medical services. We have access to 
all primary and secondary care records. Outcome is censored at the point of last medical 
contact in primary or secondary care. Data regarding deaths were collected from the 
hospital’s electronic systems and were entered into a dedicated database, stored on a secure 
NHS server.  
 
Statistical analysis 
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Continuous data are expressed as a median with interquartile range (IQR) (25
th
 to 
75
th
 centiles) and categorical data are expressed as n (%). Independent t tests and non-
parametric tests were used to compare medians across ordered groups for normally and non-
normally distributed variables, respectively.  The chi-squared test was used to compare 
proportions between groups.  Pearson’s correlation coefficients were used to assess the 
correlations between pairs of variables. Venn diagrams were used to illustrate the relationship 
between indices.  
 
Time-to-event data are presented graphically using Kaplan-Meier curves. Log-rank-tests were 
used to compare survival between groups. Univariable and multivariable analyses with Cox 
proportional hazard regression were used to determine significant predictors of events. Log-
transformation was applied when the data were very right-skewed. 
 
Cross-validation, using an intuitive approach, brings both consistency and variability to 
prognostic model development.
13
 The ‘one-stop prognostic model’ approach, although still 
favoured by many, fell into disrepute more than 30 years ago.
14
 We therefore used k-fold 
cross-validation (k=25 here) to generate 25 prognostic models. Crossfold-validation splits the 
data randomly into 25 partitions.  For each partition, the specified Cox regression model was 
fitted using the other k-1 (i.e., 24) groups, and the results were used to predict the dependent 
variable in the unused group.   
 
The variables listed in Appendix 3 and 4 were included in the Cox models except: albumin, 
cholesterol and lymphocyte count which are included in the CONUT score and PNI; and 
weight, height and BMI which are included in the GNRI.  
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An arbitrary level of 5% statistical significance (two-tailed) was assumed for a covariate to be 
included in the model. The frequency of inclusion in all 25 prognostic models was 
calculated.  Variables with an arbitrary inclusion frequency of ≥ 18 (in at least 70% of the 25 
prognostic models) were used to form a malnutrition base model. Variables adjusted for in 
the base model included: age, sex, diastolic blood pressure, heart rate, New York Heart 
Association class III+ IV vs I+II, urea, logNTproBNP, CVA and PVD. We added each of the 
malnutrition indices and BMI alone (linear and decile) in turn to the base model and used 
Harrell’s concordance (C) index15 and log-likelihood ratio (LLR) to evaluate model 
discrimination in survival analysis, whilst noting that C-index is overoptimistic for censored 
survival data.
16
  The C-index is defined as the probability that predictions and outcomes are 
concordant (the same).  A C-index of 0.5 means that the relationship is no better than chance.  
The more negative the LLR, the bigger the improvement in model performance from addition 
of malnutrition indices to base model. 
 
All statistical analyses were performed using SPSS 22 (SPSS INc.,Chicago, IL, USA) and 
The Stata (14
th
 Version, StataCorp, TX, USA) statistical computer package. 
 
Results 
Patient characteristics  
Of the 4,021 patients enrolled, 3,386 had HF: 1,198 (35%) patients had HeFREF, 2,188 
(65%) patients had HeFNEF and 635 did not have HF.  Most patients with HF were men 
(61%) and median age was 75 years (IQR: 67-81). Median LVEF was 44% (IQR: 33-56%) 
and median NTproBNP was 1,103 (IQR: 415-2,631) ng/L). A third of patients (30%) had 
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severe symptoms (New York Heart Association (NYHA) class III or IV), the most common 
co-morbid condition was IHD (48% of cases), and 36% were obese (BMI ≥ 30 kg/m2).  
Baseline characteristics of patients with HeFREF, HeFNEF and patients without HF are 
shown in Table 1. 
 
Prevalence and clinical associations of malnutrition 
By GNRI and CONUT score, 316 (9%) and 1,486 (44%) patients with HF had mild 
malnutrition, respectively. By GNRI, CONUT score and PNI, 228 (7%), 339 (10%) and 255 
(8%) patients had moderate to severe malnutrition, respectively (Table 1 and Online tables 
2a-c). Although malnutrition scores correlated with each other (CONUT vs GNRI: 
correlation coefficient (r) = 0.36; CONUT vs PNI: r = 0.72; GNRI vs PNI: r = 0.42, all 
p<0.001), only 5% were classified as malnourished (any degree of malnutrition) by all three 
scores, and only 42% were not malnourished by any (Online figure 2). Because PNI has no 
“mild” category for malnutrition, the overlap amongst patients identified as moderately or 
severely malnourished by the different scores is more striking.  
 
Compared to those with normal nutritional status, patients with malnutrition measured by any 
of the three malnutrition scores were older, more likely to be men, had lower BMI, worse 
symptoms and renal function; they were also more likely to have atrial fibrillation, anaemia 
and reduced mobility. (Online tables 2a-c) By CONUT score, 54% of patients with HeFREF 
and HeFNEF were malnourished, whilst fewer than 30% of those without HF were 
malnourished. By GNRI, malnutrition was more common in patients with HeFREF (19%) 
than HeFNEF (14%) or patients without HF (4%).  By PNI, malnutrition was equally 
common in patients with HeFREF (8%) and HeFNEF (7%), whilst it was rare in patients 
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without HF (Table 1).  The prevalence of moderate to severe malnutrition measured by any of 
the three indices was much higher in patients with plasma NTproBNP >4000 ng/L (Table 2). 
 
Not surprisingly, the highest prevalence of malnutrition was found in patients who were 
underweight (BMI<18.5kg/m
2
; 1.4% of patients with HF). A substantial proportion of 
patients with BMI >30 kg/m
2
 (36% of patients with HF) were malnourished defined by 
CONUT (50%) or PNI (5%) scores but none by GNRI. (Table 2) 
 
Malnutrition scores and mortality 
During a median follow-up of 1,573 days (interquartile range: 702-2,799 days), 1,723 
(50.9%) patients died; 351 (10%), 600 (18%) and 818 (24%) after one, two and three years, 
respectively. Worsening malnutrition status was associated with worse outcome regardless of 
the malnutrition screening tool used (Figure 1). 
 
Univariable and multivariable predictors of mortality for the overall population and for the 
different HF phenotypes are shown in table 3 and Online tables 3a-b. Worsening malnutrition 
was associated with worse outcome regardless of left ventricular ejection fraction.  
 
The following variables were independently associated with adverse outcome in 100% of the 
25 prognostic Cox regression models developed using cross-validation: increasing age, urea, 
NTproBNP, NYHA class (III/IV vs I/II), worse CONUT or GNRI score, male sex, CVD, 
PVD and diastolic blood pressure; PNI was an independent predictor in 20 models (80%) 
(Online table 4). 
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A base model (including age, sex, diastolic blood pressure, heart rate, NYHA class III/IV vs  
I&II, urea, logNTproBNP, CVA and PVD) for predicting mortality achieved a Harrell’s 
concordance (C) index = 0.719.  (Table 4) Each malnutrition score, when added individually, 
improved the performance of the base model, with GNRI improving model performance 
most. Addition of BMI (linear or decile) alone did not improve performance of the base 
mode. Online table 5 summarised the findings from other studies which reported the role of 
malnutrition scores in predicting outcomes using different risk models. 
 
Patients with any indication of malnourishment who were also underweight had the worst 
outcome. For those with higher BMI, one year mortality was substantially higher in the 
presence of moderate-severe malnutrition by any of the indices used.  Patients with an 
NTproBNP >4000 ng/L and moderate or severe malnutrition had a particularly high one year 
mortality, ranging from 37 to 57% by different indices (Table 2).  
 
Discussion 
Malnutrition, as defined by existing scores, is common in out-patients with chronic heart 
failure and is associated with a poor prognosis regardless of the screening tools used, and 
regardless of the left ventricular systolic function, circulating levels of natriuretic peptides or 
body mass index. Although, malnutrition scores provided only a modest increase in the 
statistical accuracy of multi-variable prognostic models they may be important for at least 
two reasons; the wide availability of the variables required for their calculation and 
malnutrition as a potentially modifiable risk and therapeutic target.  
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The prevalence of malnutrition is, however, highly dependent upon the tool used, ranging 
from 8% (by PNI) to 54% (by CONUT) in the same cohort of patients. According to Lin et 
al. who conducted a systematic review on nutritional screening and assessment tools in heart 
failure, the prevalence of malnutrition in patients with chronic HF ranged from 16-62%.
9
 The 
differences amongst studies in the prevalence of reported malnutrition might be due either to 
differences in the severity of heart failure or the use of different scoring systems. In our 
cohort, concordance amongst scores for milder degrees of malnutrition was rather poor, 
suggesting that they are not interchangeable. However, there was a greater degree of 
concordance for moderate to severe malnutrition amongst the three scores; perhaps reflecting 
the similarity of the variables on which they are based. 
 
The CONUT score is calculated from variables reflecting protein and lipid metabolism as 
well as immune function measured from blood tests. PNI is similar to CONUT but does not 
include cholesterol. The CONUT score suggested that many more patients were 
‘malnourished’ compared to GNRI or PNI but this may reflect low plasma cholesterol due to 
statin therapy. Although the benefits of statins are dubious in heart failure,
17
 they are still 
commonly prescribed, and thus CONUT score is perhaps not the ideal tool. PNI identifies far 
fewer patients as malnourished compared to CONUT because it does not include cholesterol. 
However, as PNI only identifies patients as moderately or severely malnourished and may 
therefore underestimate the overall prevalence of malnutrition.   
 
Amongst the three screening tools used, GNRI had the greatest incremental value in 
predicting risk. GNRI is the only tool of the three malnutrition indices we studied which takes 
into account both anthropometric factors (the ratio of body weight to ideal body weight) and 
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serum markers (albumin level). The CONUT score and PNI both consider serum markers 
only. GNRI might be a better malnutrition screening tool than CONUT or PNI because it is 
multidimensional.  However, because GNRI considers low body weight to be a marker of 
malnutrition, it might underestimate malnutrition in overweight patients. 
 
Although we found that indices of malnutrition increased the prognostic value of the models 
we constructed, the modest increase in c-index is of little value for the individual patient. 
However, given the effect in a substantial population of patients, the increase in c-statistic 
does emphasise that there is some component of “malnutrition” that is related to prognosis 
above and beyond the usual clinical variables taken into account when constructing 
prognostic models.  In turn, that statistical result suggests that there may be some value in 
exploring malnutrition – and, perhaps, its treatment – further. 
 
In patients with heart failure, BMI is not an ideal measure of body size and composition, and 
should not be used a surrogate of nutritional status. Patients with HF and higher BMI have, 
on average, lower plasma concentrations of natriuretic peptides and better outcomes than 
those with lower BMI, a phenomenon sometimes termed the ‘obesity paradox’.18 Using 
CONUT and PNI criteria, malnutrition is not only common in underweight patients, but is 
also highly prevalent in those who are overweight, obese, or even morbidly obese. We have 
found that the malnutrition scores we used were more highly related to outcome than BMI, 
and that their inclusion in predictive models of outcome increased the predictive power of the 
models, whereas including BMI did not. Despite the apparent protective effects of greater 
BMI, overweight patients who are malnourished by these two indexes have a higher mortality 
Sze et al. Malnutrition in HF V_JACC_HF 6.2.2018  
14 
 
than those who do not, highlighting that malnutrition does not simply manifest as being 
underweight.  
 
Once present, malnutrition may progress to overt cardiac cachexia, a global wasting process 
affecting all body compartments including skeletal muscle, fat and bone.
1 
 The causes of 
cachexia in HF are multifactorial, and might arise as a result of malnutrition, impaired protein 
and calorie balance, pro-inflammatory immune activation, neurohormonal derangement, 
physical deconditioning and prolonged immobilisation leading to catabolic anabolic 
imbalance.
19
 Screening for malnutrition using the most appropriate tool for patients with 
heart failure might enable early identification and characterisation of patients at risk of 
developing cachexia. Future studies should focus on studying whether better use of available 
treatments or novel treatments might improve nutritional status and eventually outcomes in 
these at-risk HF patients.  
 
Study limitations 
This is a single-centre study which has advantages and disadvantages. It is much easier to 
develop a system to enrol a large number of consecutive patients and apply consistent criteria 
and evaluations in a single centre. On the other hand, our patients and processes may differ 
from other centres. However, variations in patient selection amongst centres, often coupled 
with poor enrolment may make multi-centre studies less epidemiologically representative 
than a well-conducted single centre study. Nonetheless, confirmation of our findings by other 
investigators and other countries with different healthcare and social systems would be 
welcome. We used only three of the large number scores developed to screen for 
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malnutrition. We did not compare the prognostic value of nutritional screening tools with 
more complex comprehensive nutritional assessments.
20
  
 
Whether it is appropriate to attribute low serum albumin solely to malnutrition is unclear. 
Hepatic disease and congestion or protein-losing gastro-intestinal or renal disease could cause 
serum albumin to fall. Indeed, in CONUT, scores for mild malnutrition appeared to be driven 
largely by statin therapy. Some of our patients were naïve to, or required optimisation of 
treatment for heart failure, which might improve nutritional status, and outcome, particularly 
those with HeFREF. Not everyone will agree with our definition of HeFNEF, for which there 
is no universal diagnostic agreement. However, malnutrition was much more common and 
prognosis much worse for patients who fulfilled our definition of HeFNEF compared to 
patients considered not to have HF.  
 
We did not investigate the changes in nutritional status over time and the relationship 
between malnutrition scores and body composition. As reduced mobility occurred 
significantly in patients with HF who were classified as malnourished it might also be 
worthwhile to investigate whether an association between malnutrition and physical 
deconditioning exists. 
 
Conclusion 
Recognition of the high prevalence (and poor prognosis associated with) malnutrition in 
patients with heart failure should stimulate further research into its definition and 
management. We found that simple malnutrition scores were more closely related to outcome 
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than BMI, which is thus not an ideal measure of body size and composition. BMI should not 
be used as surrogate of nutritional status in patients with heart failure. 
 
Perspectives:  
Competency in Medical Knowledge 1: Malnutrition is common in ambulatory patients with 
HF, with a prevalence of up to 54% depending on severity and screening tool used. 
Malnutrition was more common when BMI was low or plasma NTproBNP was high and in 
older patients. 
Competency in Medical Knowledge 2: Malnutrition is associated with a poor prognosis 
regardless of the screening tools used, LVEF, NTproBNP or BMI.  
Translational outlook: Recognition of the high prevalence and poor prognosis of 
malnutrition in patients with HF should stimulate further research into its definition and 
management. (91 words)  
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Table 1. Baseline characteristics of all patients referred with suspected heart failure.  
 
 No HF HF  
Missing  
P-value* 
HF vs no HF 
P-value* 
HeFREF vs 
HeFNEF 
 (LVEF ≥40 % & 
NTProBNP ≤125 ng/L) 
(N=635) 
HeFREF 
(LVEF <40%) 
(N=1198) 
HeFNEF 
(LVEF ≥40% &  
NTProBNP >125 ng/L) 
(N=2188) 
Demographics 
Age (years) 67 (59-73) 73 (64-79) 76 (70-82) 0 <0.001 <0.001 
Sex (male), n (%) 342 (54) 895 (75) 1168 (53) 0 0.001 <0.001 
Height (m) 1.67 (1.60-1.74) 1.69 (1.62-1.76) 1.65 (1.58-1.73) 0 0.06 <0.001 
Weight (kg) 85 (73-97) 78 (66-90) 79(67-92) 0 <0.001 0.01 
BMI (kg/m2) 30 (27-34) 27 (24-31) 29 (25-33) 0 <0.001 <0.001 
BP systolic (mmHg) 144 (129-159) 128 (113-143) 145 (127-162) 5 <0.001 <0.001 
BP diastolic (mmHg) 82 (74-91) 76 (67-87) 78 (70-89) 5 <0.001 <0.001 
HR (bpm) 72 (64-82) 75 (64-88) 72 (62-83) 13 0.08 <0.001 
NYHA, n (%) 
I 
II 
III 
IV 
 
302 (48) 
244 (38) 
83 (13) 
5 (1) 
 
165 (14) 
598 (50) 
401 (33) 
34 (3) 
 
547 (25) 
1062 (49) 
551 (25) 
29 (1) 
0 <0.001 <0.001 
Comorbidities 
CVA, n (%) 20 (3) 104 (9) 133 (6) 0 <0.001 0.004 
IHD, n (%) 153 (24) 768 (64) 838 (38) 0 <0.001 <0.001 
PVD, n (%) 13 (2) 72 (6) 74 (3) 0 0.007 <0.001 
Diabetes, n (%) 169 (27) 274 (23) 546 (25) 0 0.19 0.18 
HTN, n (%) 252 (40) 367 (31) 878 (40) 0 0.16 <0.001 
COPD, n (%) 63 (10) 113 (9) 212 (10) 0 0.80 0.81 
Cancer, n (%) 33 (5) 94 (8) 208 (10) 0 0.002 0.11 
Significantly deranged liver 
function test, n (%) 
2 (0) 9 (1) 7 (0) 0 0.59 0.08 
Reduced mobility, n (%) 210 (33) 620 (52) 1203 (55) 0 <0.001 0.07 
Blood tests 
Hb (g/dL) 14.0 (13.2-15.0) 13.5 (12.3-14.7) 13.2 (12.0-14.3) 10 <0.001 <0.001 
Urea (mmol/L) 5.2 (4.2-6.3) 7.1 (5.4-9.9) 6.6 (5.1-9.1) 1 <0.001 <0.001 
Creatinine (umol/L) 82 (71-96) 105 (88-133) 95 (79-121) 7 <0.001 <0.001 
K+ (mmol/L) 4.3 (4.0-4.5) 4.4 (4.1-4.7) 4.3 (4.0-4.6) 24 <0.001 0.003 
Na+ (mmol/L) 139 (137-141) 139 (136-140) 139(137-140) 6 <0.001 0.009 
Lymphocyte  (x109/L) 1.9 (1.6-2.3) 1.6 (1.2-2.1) 1.7 (1.3-2.1) 0 <0.001 0.46 
Albumin (g/L) 40 (37-41) 38 (35-40) 38 (35-40) 0 <0.001 0.09 
Cholesterol (mmol/L) 4.9 (4.1-5.8) 4.4 (3.7-5.3) 4.5 (3.7-5.4) 0 <0.001 0.08 
NTproBNP (ng/L) 64 (38-92) 1974 (831-4534) 812(309-1845) 0 NA <0.001 
Treatment at Referral 
Loop diuretic, n (%) 184 (29) 904 (76) 1243 (57) 42 <0.001 <0.001 
MRA, n (%) 23 (4) 369 (31) 262 (12) 42 <0.001 <0.001 
ACEi, n (%) 226 (36) 858 (72) 1094 (51) 42 <0.001 <0.001 
ARB, n (%) 69 (11) 112 (9) 280 (13) 42 0.63 0.003 
ACEi or ARB, n (%) 292 (47) 966 (81) 1349 (62) 42 <0.001 <0.001 
BB, n (%) 169 (27) 758 (64) 1119 (52) 42 <0.001 <0.001 
Statin, n (%) 299 (48) 634 (53) 1093 (51) 42 0.09 0.10 
Digoxin, n (%) 10 (2) 203 (17) 384 (18) 42 <0.001 0.65 
ECG and echocardiography 
Cardiac rhythm, n (%) 
AF 
Sinus 
Unknown 
 
0 
628 (99) 
6 (1) 
 
278 (23) 
833 (70) 
87 (7) 
 
695 (32) 
1382 (63) 
112 (5) 
0 <0.001 <0.001 
EF (%) 59 (54-64) 30 (25-35) 54 (46-60) 1779 <0.001 NA 
LV impairment , n (%) 
None/trivial 
Mild / mild- moderate 
Moderate to severe 
 
581 (91) 
54 (9) 
0 
 
0 
108 (9) 
1090 (91) 
 
1499 (69) 
634 (29) 
55 (2) 
0 <0.001 <0.001 
LVEDD (cm) 4.8 (4.4-5.2) 6.2 (5.7-6.8) 5.0 (4.5-5.5) 619 <0.001 <0.001 
Malnutrition 
Prevalence of malnutrition 
CONUT 
Normal (0-1) 
Mild malnutrition (2-4) 
Moderate malnutrition (5-8) 
Severe malnutrition (9-12) 
GNRI 
Normal (>98) 
Mild malnutrition (92-98) 
Moderate malnutrition (82-91) 
Severe malnutrition (<82) 
PNI 
Normal (>38) 
Moderate malnutrition (35-38) 
Severe malnutrition (<38) 
 
 
450 (71) 
181 (29) 
3 (<1) 
0 
 
614 (96) 
16 (3) 
4 (1) 
0 
 
633 (100) 
1 (0) 
0  
 
 
552 (46) 
507 (42) 
129 (11) 
10 (1) 
 
969 (81) 
133 (11) 
71 (6) 
25 (2) 
 
1101 (92) 
53 (4) 
44 (4) 
 
 
1010 (46) 
979 (45) 
190 (9) 
10 (<1) 
 
1874 (86) 
183 (8) 
106 (5) 
26 (1) 
 
2023 (93) 
86 (4) 
72 (3) 
 
 
0 
 
 
 
 
0 
 
 
 
 
0 
 
 
 
<0.001 
 
 
 
 
<0.001 
 
 
 
 
<0.001 
 
 
0.09 
 
 
 
 
0.003 
 
 
 
 
0.65 
 
 ACEi = Angiotensin-converting enzyme inhibitor, AF= atrial fibrillation, ARB = Angiotensin receptor blocker, BB= betablocker, BMI= body mass index, BP= blood pressure, CONUT = 
Controlling nutritional status, CVA = cerebrovascular disease, ECG= electrocardiogram. EF= ejection fraction,  GNRI = Geriatric nutritional risk index, Hb = Haemoglobin, HF= heart failure, 
HeFREF = heart failure with reduced ejection fraction, HeFNEF = heart failure with normal ejection fraction, HR= heart rate, IHD = ischaemic heart disease, HTN= hypertension, COPD = 
chronic obstructive pulmonary disease, K+ = potassium, LVEDD= left ventricular end diastolic diameter, MRA = Mineralocorticoids receptor antagonists,  Na+ = sodium, NYHA = New York 
Heart Association Class, NTproBNP = N-terminal Pro Brain Natriuretic Peptide, PNI = Prognostic nutritional Index, PVD = peripheral vascular disease. 
 
*P-value for trend except when there are > 2 categories (e.g. NYHA class, cardiac rhythm etc) 
Table 2: Prevalence of malnutrition and 1-year mortality of patients with heart failure stratified by BMI and NTproBNP. 
 BMI Categories (kg/m
2
) 
Underweight 
<18.5 
(N=48) 
Normal 
18.5-24.9 
(N=854) 
Overweight 
25-29.9 
(N=1256) 
Obese 
30-39.9 
(N=1061) 
Morbidly obese 
≥40 
(N=167) 
C
O
N
U
T
 
% malnourished (any degree) 77 59 54 49 56 
%  malnourished (mod-sev) 21 15 9 7 11 
1 year mortality (%) 
Malnutrition (mod-sev vs mild vs none) 
56 vs 42 vs 9 38 vs 17 vs 8 23 vs 11 vs 6 17 vs 9 vs 5 33 vs 5 vs 9 
G
N
R
I 
% malnourished (any degree) 96 49 6 0 0 
% malnourished (mod-sev) 88 20 1 0 0 
1 year mortality (%) 
Malnutrition (mod-sev vs mild vs none) 
40 vs 0 vs 50 41 vs 15 vs 8 43 vs 9  NA NA 
P
N
I 
%  malnourished (mod-sev) 26 11 7 4 7 
1 year mortality (%) 
Malnutrition (mod-sev vs none) 
50 vs 32 50 vs 12 26 vs 9 24 vs 7 36 vs 8 
*There are only two underweight (BMI < 18.5 kg/m2) patients classified as not malnourished by GNRI. There is no underweight patient classified as mildly malnourished by 
GNRI.  
CONUT = Controlling nutritional status, GNRI = Geriatric nutritional risk index, HF= heart failure, Mod-sev = moderate to severe, NTproBNP = N-terminal Pro Brain 
Natriuretic Peptide, PNI = Prognostic nutritional Index. 
 NTproBNP categories (ng/L) 
≤400 
(N=822) 
401-1000 
(N=776) 
1001-2000 
(N=697) 
2001-4000 
(N=553) 
>4000 
(N=538) 
C
O
N
U
T
 
% malnourished (any degree) 39 47 54 62 78 
%  malnourished (mod-sev) 3 4 8 12 31 
1 year mortality (%) 
Malnutrition (mod-sev vs mild vs none) 
10 vs 4 vs 3 19 vs 8 vs 5 20 vs 11 vs 5 25 vs 12 vs 11 37 vs 31 vs 20 
G
N
R
I 
% malnourished (any degree) 5 10 15 22 38 
%  malnourished (mod-sev) 2 4 5 7 20 
1 year mortality (%) 
Malnutrition (mod-sev vs mild vs none) 
29 vs 7 vs 3 25 vs 5 vs 6 25 vs 13 vs 8  28 vs 14 vs 12 57 vs 30 vs 22 
P
N
I 
%  malnourished (mod-sev) 2 3 6 9 23 
1 year mortality (%) 
Malnutrition (mod-sev vs none) 
20 vs 3 27 vs 6 26 vs 8 30 vs 12 47 vs 25 
Table 3: Univariable and multivariable analyses of factors predicting mortality in patients with CHF (overall population) 
Worse outcome per unitary 
increase 
Overall HF population  
Univariate Multivariate 
HR(95%CI) Wald Χ2 P-value HR(95%CI) Wald Χ2 P-value 
Age (years) 1.055 (1.05-1.06) 362.8 <0.001 1.05 (1.04-1.06) 209.0 <0.001 
Sex (male vs female) 1.17 (1.06-1.29) 10.0 0.002 1.29 (1.15-1.45) 18.1 <0.001 
Height (m) 0.26 (0.17-0.42) 32.4 <0.001    
Weight (kg) 0.99 (0.986-0.991) 70.5 <0.001    
BMI (kg/m
2
) 0.97 (0.96-0.98) 41.6 <0.001    
BP systolic (mmHg) 0.99 (0.99-1.00) 34.1 <0.001    
BP diastolic (mmHg) 0.98 (0.98-0.98) 129.6 <0.001 0.99 (0.99-1.00) 14.7 <0.001 
HR (bpm) 1.01 (1.00-1.01) 22.9 <0.001 1.01 (1.00-1.01) 9.7 0.002 
NYHA 
III/IV vs I/II 
2.03 (1.84-2.24) 200.7 <0.001 1.56 (1.40-1.74) 64.4 <0.001 
Hb (g/dL) 0.82 (0.80-0.85) 195.4 <0.001    
Urea (mmol/L) 1.06 (1.05-1.06) 343.2 <0.001 1.03 (1.02-1.04) 21.8 <0.001 
Creatinine (umol/L) 1.00 (1.00-1.00) 183.1 <0.001    
K+ (mmol/L) 1.01 (0.91-1.11) 0.02 0.90    
Na+ (mmol/L) 0.94 (0.93-0.95) 76.8 <0.001    
Lymphocyte  (x10
9
/L) 0.67 (0.62-0.72) 100.7 <0.001    
Albumin (g/L) 0.90 (0.88-0.91) 328.1 <0.001    
Cholesterol (mmol/L) 0.94 (0.90-0.97) 12.0 0.001    
Log NTproBNP (ng/L) 2.80 (2.57-3.06) 524.7 <0.001 1.75(1.56-1.97) 93.0 <0.001 
Loop diuretic (Y vs N) 2.10 (1.90-2.40) 180.6 <0.001    
MRA (Y vs N) 1.21 (1.08-1.37) 9.9 0.002    
ACEi (Y vs N) 1.04 (0.94-1.14) 0.5 0.46    
ARB (Y vs N) 0.89 (0.75-1.04) 2.2 0.14    
ACEi or ARB (Y vs N) 1.00 (0.90-1.11) 0.003 0.96    
BB (Y vs N) 0.70 (0.64-0.77) 53.3 <0.001    
Statin (Y vs N) 0.77 (0.70-0.84) 30.0 <0.001    
Digoxin (Y vs N) 1.43 (1.27-1.60) 35.2 <0.001    
Cardiac rhythm 
AF vs Sinus 
 
1.32 (1.19-1.47) 
 
26.3 
 
<0.001 
   
EF (%) 0.99 (0.98-0.99) 36.7 <0.001    
LVEDD (cm) 1.05 (1.00-1.11) 4.0 0.046    
CVA (Y vs N) 1.55 (1.31-1.83) 26.8 <0.001    
IHD (Y vs N) 1.11 (1.01-1.22) 4.8 0.029    
PVD (Y vs N) 1.80 (1.48-2.20) 34.0 <0.001 1.66 (1.35-2.05) 22.7 <0.001 
Diabetes (Y vs N) 1.13 (1.01-1.27) 4.2 0.04    
Reduced mobility (Y vs N) 2.11 (1.89-2.36) 175.1 <0.001    
Prevalence of malnutrition 
 
CONUT 
Normal 
Mild malnutrition 
Moderate malnutrition 
Severe malnutrition 
 
 
 
1 
1.58 (1.43-1.75) 
2.96 (2.54-3.45) 
9.41 (5.89-15.06) 
 
 
 
- 
76.0 
195.3 
87.5 
 
 
 
<0.001 
<0.001 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACEi = Angiotensin-converting enzyme inhibitor, AF= atrial fibrillation, ARB = Angiotensin receptor blocker, BB= betablocker, BMI= body mass index, BP= blood pressure, CONUT = 
Controlling nutritional status, CVA = cerebrovascular disease, ECG= electrocardiogram. EF= ejection fraction,  GNRI = Geriatric nutritional risk index, Hb = Haemoglobin, HF= heart failure, 
HeFREF = heart failure with reduced ejection fraction, HeFNEF = heart failure with normal ejection fraction, HR= heart rate, IHD = ischaemic heart disease, K+ = potassium, LVEDD= left 
ventricular end diastolic diameter, MRA = Mineralocorticoids receptor antagonists,  Na+ = sodium, NYHA = New York Heart Association Class, NTproBNP = N-terminal Pro Brain Natriuretic 
Peptide, PNI = Prognostic nutritional Index, PVD = peripheral vascular disease, Y= yes, N=No. 
 
 
GNRI 
Normal 
Mild malnutrition 
Moderate malnutrition 
Severe malnutrition 
 
PNI 
Normal 
Moderate malnutrition 
Severe malnutrition 
 
 
 
1 
1.72 (1.48-2.00) 
2.68 (2.23-3.22) 
6.14 (4.49-8.40) 
 
 
1 
2.75 (2.26-3.36) 
2.99 (2.41-3.72) 
 
 
 
- 
50.8 
111.4 
129.2 
 
 
- 
101.2 
97.4 
 
 
- 
<0.001 
<0.001 
<0.001 
 
 
- 
<0.001 
<0.001 
 
 
1.26 (1.15-1.37) 
 
27.2 
 
<0.001 
Table 4: Addition of malnutrition indices to base model improves model performance in 
predicting all-cause mortality. Improvement in model performance was measured using 
Harrell’s concordance (C) index and log-likelihood ratio (LLR) – the more negative the LLR, 
the bigger the improvement in model performance. Amongst the malnutrition scores, GNRI 
improves model performance most compared with base model. 
 
Model C LLR 
improvement 
from base 
P-value for LLR 
improvement from base 
Base model* 0.719   
Base* + CONUT score 0.721 -16.2 0.001 
Base* + GNRI 0.724 -31.4 <0.001 
Base* + PNI 0.721 -12.1 0.002 
Base* + BMI (linear) 0.719 0 NA 
Base* + BMI (decile) 0.720 -13.0 0.16 
 
*Variables adjusted for in the base model: age, sex, diastolic blood pressure, heart rate, New 
York Heart Association class III+ IV vs I+II, urea, logNTproBNP, CVA, PVD. The model + 
CONUT score from base means that CONUT has been 'adjusted' for our 9 covariates. 
 
 
CONUT = Controlling nutritional status, CVA = cerebrovascular disease, GNRI = Geriatric nutritional risk index, 
NTproBNP = N-terminal Pro Brain Natriuretic Peptide, PNI = Prognostic nutritional Index, PVD = peripheral vascular 
disease. 
 
Online figure 1: Recruitment of chronic heart failure patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLL = chronic lymphocytic leukaemia, HeFREF = heart failure with reduced ejection fraction, HeFNEF= heart failure with normal ejection fraction, HF= heart failure,  
 LVEF= left ventricular ejection fraction, NTproBNP = N-terminal Pro Brain Natriuretic Peptide. 
No height or weight (N=69)  
CLL (N=6) 
Total cohort (N=4865) 
No NTproBNP (N= 769) 
HFeREF (N=1198) 
LVEF<40% or moderate-
severe left ventricular 
systolic dysfunction 
HeFNEF (N=2188) 
LVEF ≥40% or ≤ mild- 
moderate left ventricular 
systolic dysfunction & 
NTproBNP >125 ng/L 
No HF (N=635) 
 LVEF ≥40 % or ≤ mild left 
ventricular systolic 
dysfunction & NTproBNP 
≤125 ng/L 
Online figure 2: Prevalence of malnutrition (any degree versus moderate to severe) in our HF cohort according to CONUT score, GNRI and PNI.  
 
Online table 1: Procedures for evaluation of each nutritional index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nutritional Indices Degree of malnutrition 
Normal Mild Moderate Severe 
Controlling Nutritional Status (CONUT) score 
9 
  Albumin, g/L (score) 
  Cholesterol, mmol/L (score) 
  Total Lymphocyte count , x10
9
/L (score) 
  Overall score 
 
Geriatric Nutritional risk index (GNRI) 
10
 
= 1.489 x serum albumin (g/L) + 41.7 x (body weight in 
kilograms / ideal body weight)  
 
Prognostic nutritional index (PNI) 
11
 
= 10 x serum albumin (g/dL) + 0.005 x total lymphocyte count 
(mm
3
) 
 
 
≥35 (0) 
>4.65 (0) 
≥1.60 (0) 
0-1 
 
 
>98 
 
 
 
>38 
 
30-34 (2) 
3.62-4.65 (1) 
1.20-1.59 (1) 
2-4 
 
 
92-98 
 
 
 
- 
 
25-29 (4) 
2.59-3.61 (2) 
0.80-1.19 (2) 
5-8 
 
 
82-91 
 
 
 
35-38 
 
<25 (6) 
<2.59 (3) 
<0.80 (3) 
9-12 
 
 
<82 
 
 
 
<35 
Online table 2a: Baseline characteristics of the heart failure cohort by CONUT categories 
 CONUT Score Overall  
Median (25th, 
75th centiles) or n 
(%) 
(N=3386) 
Missing P-value 
amongst 
malnutrition 
groups* 
 
0-1  
Normal  
(N= 1561) 
2-4 
Mild malnutrition 
(N=1486) 
5-8 
Moderate malnutrition 
(N=319) 
9-12 
Severe malnutrition 
(N=20) 
Age (years) 73 (65-80) 75 (69-81) 77 (71-82) 78 (69-83) 75 (67-81) - <0.001 
Sex (male), n(%) 851 (55) 964 (65) 233 (73) 15 (75) 2063 (61) - <0.001 
Height (m) 1.66 (1.58-1.74) 1.68 (1.60-1.74) 1.68 (1.61-1.75) 1.70 (1.61-1.76) 1.67 (1.59-1.74) - 0.012 
Weight (kg) 79 (68-91) 79 (67-91) 75 (64-87) 70 (65-86) 78 (67-91) - 0.037 
BMI (kg/m2) 29 (25-32) 28 (25-32) 26(24-30) 25 (22-30) 28 (25-32) - <0.001 
BP systolic (mmHg) 140 (124-160) 139 (121-156) 126 (110-149) 105 (94-119) 139 (121-157) 4 <0.001 
BP diastolic (mmHg) 80 (71-90) 77 (68-87) 72 (63-81) 60 (56-70) 78 (69-88) 3 <0.001 
HR (bpm) 72 (63-84) 71 (62-84) 78 (64-89) 78 (70-88) 72 (62-85) 13 0.001 
NYHA, n(%) 
I 
II 
III 
 
388 (25) 
817 (52) 
336 (22) 
 
291 (20) 
705 (47) 
463 (31) 
 
31 (10) 
132 (41) 
142 (45) 
 
1 (5) 
6 (30) 
11 (55) 
 
711 (21) 
1660 (49) 
952 (28) 
- <0.001 
IV 20 (1) 27 (2) 14 (4) 2 (10) 63 (2) 
Hb (g/dL) 13.7 (12.7-14.8) 13.1 (12.0-14.2) 11.8 (10.6-12.9) 10.8 (9.6-12.9) 13.3 (12.1-14.4) 10 <0.001 
Urea (mmol/L) 6.4 (5.0-8.6) 7.0 (5.3-9.5) 8.5 (6.1-12.5) 10.6 (8.2-12.5) 6.8 (5.2-9.3) 1 <0.001 
Creatinine (umol/L) 94 (79-115) 103 (83-129) 117 (91-162) 134 (97-177) 100 (81-126) 7 <0.001 
K+ (mmol/L) 4.3 (4.1-4.7) 4.3 (4.0-4.6) 4.3 (4.0-4.7) 4.1 (3.9-4.6) 4.3 (4.0-4.6) 18 0.051 
Na+ (mmol/L) 139 (137-141) 139 (136-140) 138 (135-140) 135 (133-138) 139 (137-140) 5 <0.001 
Lymphocyte  (x109/L) 1.9 (1.7-2.3) 1.4 (1.1-1.8) 1.1 (0.8-1.4) 0.6 (0.5-0.9) 1.6 (1.2-2.1) - <0.001 
Albumin (g/L) 39 (37-41) 37 (35-39) 32 (29-34) 24 (22-28) 38 (35-40) - <0.001 
Cholesterol (mmol/L) 5.1 (4.4-5.9) 4.0 (3.4-4.8) 3.5 (2.9-4.2) 2.9 (2.5-3.3) 4.5 (3.7-5.4) - <0.001 
NTproBNP (ng/L) 790 (305-1772) 1291 (498-2935) 3873 (1516-7693) 6071 (2223-20466) 1103 (415-2631) - <0.001 
Loop diuretic, n(%) 919 (59) 977 (67) 234 (74) 17 (85) 2147 (64) 34 <0.001 
MRA, n(%) 266 (17) 309 (21) 50 (16) 6 (30) 631 (19) 34 0.012 
ACEi, n(%) 891 (58) 884 (60) 170 (54) 7 (35) 1952 (58) 34 0.023 
ARB, n(%) 187 (12) 169 (12) 33 (11) 3 (15) 392 (12) 34 0.82 
ACEi or ARB, n(%) 1070 (69) 1033 (70) 203 (64) 9 (45) 2315 (69) 34 0.021 
BB, n(%) 858 (55) 839 (57) 169 (54) 10 (50) 1876 (56) 34 0.57 
Statin, n(%) 685 (44) 850 (58) 180 (57) 11 (55) 1726 (52) 34 <0.001 
Digoxin, n(%) 248 (16) 253 (17) 80 (25) 6 (30) 587 (18) 34 <0.001 
Cardiac rhythm, n(%) 
AF 
Sinus 
Unknown 
 
380 (24) 
1103 (71) 
78 (5) 
 
465 (31) 
925 (62) 
96 (7) 
 
119 (37) 
178 (56) 
22 (7) 
 
9 (45) 
8 (40) 
3 (15) 
 
973 (29) 
2214 (65) 
199 (6) 
- <0.001 
EF (%) 45 (33-56) 44 (33-56) 41 (29-52) 39 (30-55) 44 (33-56) 1558 0.038 
LV impairment, n(%) 
None/trivial 
Mild/ mild-moderate 
Moderate-severe 
 
726 (47) 
319 (20) 
561 (33) 
 
654 (44) 
338 (23) 
494 (33) 
 
115 (36) 
80 (25) 
124 (39) 
 
7 (35) 
5 (25) 
8 (40) 
 
1502 (44) 
742 (22) 
1142 (34) 
- 0.03 
HF phenotype, n(%) 
 
HeFREF 
 
HeFNEF 
 
 
552 (35) 
 
1009 (65) 
 
 
 
507 (34) 
 
979 (66) 
 
 
 
129 (41) 
 
190 (59) 
 
 
 
10 (50) 
 
10 (50) 
 
 
1198 (35) 
 
2188 (65) 
 
- 0.024 
LVEDD (cm) 5.3 (4.7-6.1) 5.4 (4.8-6.1) 5.4 (4.8-6.2) 5.6 (4.8-6.2) 5.4 (4.8-6.1) 517 0.49 
CVA, n(%) 91 (6) 107 (7) 36 (11) 3 (15) 237 (7) - 0.002 
IHD, n(%) 666 (43) 775 (52) 154 (48) 11 (55) 1606 (48) - <0.001 
PVD, n(%) 54 (4) 70 (5) 22 (7) 0  146 (4) - 0.025 
Diabetes, n(%) 310 (21) 411 (29) 96 (32) 2 (11) 819 (26) - <0.001 
Reduced mobility, n(%) 739 (56) 859 (67) 210 (76) 15 (94) 1823 (63) - <0.001 
HTN, n (%) 593 (38) 549 (37) 97 (30) 6 (30) 1245 (37) - 0.07 
COPD, n (%) 136 (9) 150 (10) 37 (12) 2 (10) 325 (10) - 0.35 
Cancer, n (%) 131 (8) 133 (9) 32 (10) 6 (30) 302 (9) - 0.008 
Significantly deranged 
liver function test,       
n (%) 
7 (0) 3 (0) 5 (2) 1 (5) 16 (1) - <0.001 
 
 
 
 
 
 
 
 
 
Online table 2b: Baseline characteristics of the heart failure cohort by GNRI categories 
 GNRI Overall  
Median (25th, 
75th centiles) or n 
(%) 
(N=3386) 
Missing P-value 
amongst 
malnutrition 
groups* 
 
>98 
Normal  
(N= 2842) 
92-98 
Mild malnutrition 
(N=316) 
82-91 
Moderate malnutrition 
(N=177) 
<82 
Severe malnutrition 
(N=51) 
Age (years) 74 (67-80) 78 (72-84) 78 (72-83) 79 (74-84) 75 (67-81) - <0.001 
Sex (male) , n(%) 1757 (62) 182 (58) 97 (55) 27 (53) 2063 (61) - 0.086 
Height (m) 1.67 (1.59-1.75) 1.66 (1.58-1.72) 1.65 (1.58-1.72) 1.65 (1.58-1.76) 1.67 (1.59-1.74) - 0.006 
Weight (kg) 82 (71-94) 63 (56-69) 57(49-66) 55 (43-61) 78 (67-91) - <0.001 
BMI (kg/m2) 29 (26-33) 23 (21-24) 21 (19-23) 19 (17-21) 28 (25-32) - <0.001 
BP systolic (mmHg) 140 (123-158) 133 (116-151) 123 (109-148) 118 (103-136) 139 (121-157) 4 <0.001 
BP diastolic (mmHg) 79 (70-89) 74 (65-84) 70 (60-79) 68 (58-76) 78 (69-88) 3 <0.001 
HR (bpm) 72 (62-84) 77 (66-88) 77 (64-90) 82 (74-90) 72 (62-85) 13 <0.001 
NYHA, n(%) 
I 
II 
III 
 
616 (22) 
1418 (50) 
762 (27) 
 
64 (20) 
144 (46) 
101 (32) 
 
26 (15) 
82 (46) 
61 (34) 
 
5 (10) 
16 (31) 
28 (55) 
 
711 (21) 
1660 (49) 
952 (28) 
- <0.001 
IV 46 (1) 7 (2) 8 (5) 2 (4) 63 (2) 
Hb (g/dL) 13.5 (12.3-14.5) 12.6 (11.4-13.8) 12.5 (11.1-13.5) 12.0 (10.4-13.4) 13.3 (12.1-14.4) 10 <0.001 
Urea (mmol/L) 6.7 (5.2-9.2) 7.1 (5.4-10.5) 7.5 (5.6-10.5) 8.4 (5.5-11.3) 6.8 (5.2-9.3) 1 0.003 
Creatinine (umol/L) 100 (82-125) 100 (79-131) 101 (77-131) 107 (79-137) 100 (81-126) 7 0.87 
K+ (mmol/L) 4.3 (4.1-4.7) 4.4 (4.1-4.6) 4.3 (4.0-4.7) 4.3 (3.8-4.6) 4.3 (4.0-4.6) 18 0.37 
Na+ (mmol/L) 139 (137-141) 138 (136-140) 137 (134-139) 136 (134-139) 139 (137-140) 5 <0.001 
Lymphocyte  (x109/L) 1.7 (1.3-2.1) 1.4 (1.1-1.8) 1.4 (1.0-1.7) 1.2 (0.9-1.6) 1.6 (1.2-2.1) - <0.001 
Albumin (g/L) 38 (36-40) 35 (33-37) 32 (30-35) 29 (24-30) 38 (35-40) - <0.001 
Cholesterol (mmol/L) 4.5 (3.7-5.4) 4.5 (3.6-5.4) 4.4 (3.6-5.2) 4.3 (3.6-5.1) 4.5 (3.7-5.4) - 0.04 
NTproBNP (ng/L) 930 (364-2167) 2518 (1104-4757) 3016 (1266-7428) 4854 (1787-9447) 1103 (415-2631) - <0.001 
Loop diuretic, n(%) 1764 (63) 213 (68) 129 (73) 41 (85) 2147 (64) 34 <0.001 
MRA, n(%) 536 (19) 56 (18) 31 (18) 8 (17) 631 (19) 34 0.901 
ACEi, n(%) 1641 (58) 181 (58) 108 (61) 22 (46) 1952 (58) 34 0.29 
ARB, n(%) 361 (13) 15 (5) 11 (6) 5 (10) 392 (12) 34 <0.001 
ACEi or ARB, n(%) 1976 (70) 194 (62) 119 (68) 26 (54) 2315 (69) 34 0.003 
BB, n(%) 1614 (57) 161 (51) 83 (47) 18 (38) 1876 (56) 34 0.001 
Statin, n(%) 1529 (54) 121 (39) 56 (34) 17 (35) 1726 (52) 34 <0.001 
Digoxin, n(%) 442 (16) 88 (28) 42 (24) 15 (31) 587 (18) 34 <0.001 
Cardiac rhythm, n(%) 
AF 
Sinus 
Unknown 
 
803 (28) 
1872 (66) 
167 (6) 
 
100 (32) 
193 (61) 
23 (7) 
 
52 (30) 
121 (68) 
4 (2) 
 
18 (35) 
28 (55) 
5 (10) 
 
973 (29) 
2214 (65) 
199 (6) 
- 0.11 
EF (%) 45 (34-57) 39 (29-50) 41 (29-47) 37 (29-50) 44 (33-56) 1558 <0.001 
LV impairment, n (%) 
None/trivial 
Mild/ mild-moderate 
Moderate- severe 
 
1300 (46) 
624 (22) 
918 (32) 
 
124 (39) 
61 (19) 
131 (42) 
 
60 (34) 
47 (27) 
70 (39) 
 
18 (35) 
10 (20) 
23 (45) 
 
1502 (44) 
742 (22) 
1142 (34) 
0 0.001 
HF phenotype, n(%) 
 
HeFREF 
 
HeFNEF 
 
 
969 (34) 
 
1873 (66) 
 
 
 
133 (42) 
 
183 (58) 
 
 
 
71 (40) 
 
106 (60) 
 
 
 
25 (49) 
 
26 (51) 
 
 
 
1198 (35) 
 
2188 (65) 
 
- 0.001 
LVEDD (cm) 5.4 (4.8-6.1) 5.3 (4.7-6.1) 5.3 (4.7-6.2) 5.0 (4.4-5.9) 5.4 (4.8-6.1) 517 0.042 
CVA, n(%) 188 (7) 32 (10) 12 (7) 5 (10) 237 (7) - 0.11 
IHD, n(%) 1364 (48) 141 (45) 76 (43) 25 (49) 1606 (48) - 0.42 
PVD, n(%) 115 (4) 17 (5) 13 (7) 1 (2) 146 (4) - 0.11 
Diabetes, n(%) 745 (28) 45 (15) 24 (15) 5 (10) 819 (26) - <0.001 
Reduced mobility, n(%) 1507 (62) 170 (62) 111 (73) 35 (83) 1823 (63) - 0.013 
HTN, n (%) 1091 (38) 101 (32) 46 (26) 7 (14) 1245 (37) - <0.001 
COPD, n (%) 240 (8) 39 (12) 38 (22) 8 (16) 325 (10) - <0.001 
Cancer, n (%) 245 (9) 29 (9) 18 (10) 10 (20) 302 (9) - 0.05 
Significantly deranged 
liver function test, n (%) 
12 (0) 2 (1) 2 (1) 0 16 (1) - 0.53 
 
 
 
 
 
 
 
 
 
 
Online table 2c: Baseline characteristics of the heart failure cohort by PNI categories 
 PNI  
Overall  
Median (25th, 75th centiles) or 
n (%) 
(N=3386) 
Missing P-value 
amongst 
malnutrition 
groups* 
 
>38 
Normal  
(N= 3131) 
35-38 
Moderate malnutrition 
(N=139) 
<35 
Severe malnutrition 
(N=116) 
Age (years) 75 (67-81) 75 (68-82) 78 (72-82) 75 (67-81) - 0.004 
Sex (male) , n(%) 1888 (60) 95 (68) 80 (69) 2063 (61) - 0.032 
Height (m) 1.67 (1.59-1.74) 1.68 (1.62-1.73) 1.68 (1.61-1.77) 1.67 (1.59-1.74) - 0.097 
Weight (kg) 79 (67-91) 74 (65-86) 72 (61-88) 78 (67-91) - 0.002 
BMI (kg/m2) 28 (25-32) 26 (24-29) 26 (22-30) 28 (25-32) - <0.001 
BP systolic (mmHg) 139 (122-158) 124 (111-146) 125 (105-152) 139 (121-157) 4 <0.001 
BP diastolic (mmHg) 78 (69-89) 73 (63-81) 70 (59-81) 78 (69-88) 3 <0.001 
HR (bpm) 72 (62-84) 77 (69-90) 80 (68-92) 72 (62-85) 13 <0.001 
NYHA, n(%) 
I 
II 
 
692 (22) 
1563 (50) 
 
11 (8) 
59 (42) 
 
8 (7) 
38 (33) 
 
711 (21) 
1660 (49) 
- <0.001 
III 
IV 
829 (26) 
47 (2) 
58 (42) 
11 (8) 
65 (56) 
5 (4) 
952 (28) 
63 (2) 
Hb (g/dL) 13.4 (12.3-14.5) 12.0 (10.7-13.0) 11.6 (10.1-12.8) 13.3 (12.1-14.4) 10 <0.001 
Urea (mmol/L) 6.7 (5.2-9.2) 7.5 (5.3-11.4) 9.2 (6.5-12.3) 6.8 (5.2-9.3) 1 <0.001 
Creatinine (umol/L) 99 (81-124) 111 (83-147) 120 (92-169) 100 (81-126) 7 <0.001 
K+ (mmol/L) 4.3 (4.1-4.7) 4.3 (3.9-4.6) 4.3 (3.9-4.6) 4.3 (4.0-4.6) 18 0.01 
Na+ (mmol/L) 139 (137-141) 137 (135-139) 136 (134-139) 139 (137-140) 5 <0.001 
Lymphocyte  (x109/L) 1.3 (1.7-2.1) 1.1 (0.8-1.4) 0.9 (0.6-1.3) 1.6 (1.2-2.1) - <0.001 
Albumin (g/L) 38 (36-40) 31 (30-33) 27 (25-30) 38 (35-40) - <0.001 
Cholesterol (mmol/L) 4.5 (3.8-5.4) 3.9 (3.2-4.6) 3.8 (3.0-4.7) 4.5 (3.7-5.4) - <0.001 
NTproBNP (ng/L) 1008 (387-2355) 3319 (1294-7634) 5365 (1907-11284) 1103 (415-2631) - <0.001 
Loop diuretic, n(%) 1957 (63) 101 (73) 89 (80) 2147 (64) 34 <0.001 
MRA, n(%) 594 (19) 19 (14) 18 (16) 631 (19) 34 0.22 
ACEi, n(%) 1837 (59) 68 (49) 47 (42) 1952 (58) 34 <0.001 
ARB, n(%) 364 (12) 11 (8) 17 (15) 392 (12) 34 0.21 
ACEi or ARB, n(%) 2173 (70) 79 (57) 63 (56) 2315 (69) 34 <0.001 
BB, n(%) 1761 (57) 65 (47) 50 (45) 1876 (56) 34 0.004 
Statin, n(%) 1615 (52) 61 (44) 50 (45) 1726 (52) 34 0.066 
Digoxin, n(%) 515 (17) 45 (33) 27 (24) 587 (18) 34 <0.001 
Cardiac rhythm, n(%) 
AF 
Sinus 
Unknown 
 
874 (28) 
2078 (66) 
179 (6) 
 
51 (37) 
76 (55) 
12 (8) 
 
48 (41) 
60 (52) 
8 (7) 
 
973 (29) 
2214 (65) 
199 (6) 
- 0.001 
EF (%) 45 (33-56) 41 (30-54) 42 (28-50) 44 (33-56) 1558 0.10 
LV impairment, n(%) 
None/trivial 
Mild/mild-moderate 
Moderate-severe 
 
1401 (45) 
685 (22) 
1045 (33) 
 
56 (40) 
26 (19) 
57 (41) 
 
45 (39) 
31 (27) 
40 (34) 
 
1502 (44) 
742 (22) 
1142 (34) 
0 0.23 
HF phenotype, n(%) 
 
HeFREF 
 
HeFNEF 
 
 
1101 (35) 
 
2030 (65) 
 
 
 
53 (38) 
 
86 (62) 
 
 
 
44 (38) 
 
72 (62) 
 
 
 
1198 (35) 
 
2188 (65) 
 
- 0.54 
LVEDD (cm) 5.4 (4.8-6.1) 5.5 (4.8-6.2) 5.3 (4.6-6.1) 5.4 (4.8-6.1) 517 0.46 
CVA, n(%) 207 (7) 16 (12) 14 (12) 237 (7) - 0.008 
IHD, n(%) 1499 (48) 55 (40) 52 (45) 1606 (48) - 0.14 
PVD, n(%) 130 (4) 10 (7) 6 (5) 146 (4) - 0.20 
Diabetes, n(%) 755 (25) 34 (27) 30 (28) 819 (26) - 0.91 
Reduced mobility, n(%) 1646 (62) 101 (82) 76 (80) 1823 (63) - <0.001 
HTN, n (%) 1166 (37) 42 (30) 37 (32) 1245 (37) - 0.13 
COPD, n (%) 287 (9) 27 (19) 11 (10) 325 (10) - <0.001 
Cancer, n (%) 269 (9) 19 (14) 14 (12) 302 (9) - 0.06 
Significantly deranged 
liver function test,n (%) 
11 (0) 3 (2) 2 (2) 16 (1) - 0.001 
ACEi = Angiotensin-converting enzyme inhibitor, AF= atrial fibrillation, ARB = Angiotensin receptor blocker, BB= betablocker, BMI= body mass index, BP= blood pressure, CONUT = 
Controlling nutritional status, CVA = cerebrovascular disease, ECG= electrocardiogram. EF= ejection fraction,  GNRI = Geriatric nutritional risk index, Hb = Haemoglobin, HF= heart failure, 
HeFREF = heart failure with reduced ejection fraction, HeFNEF = heart failure with normal ejection fraction, HR= heart rate, IHD = ischaemic heart disease, K+ = potassium, LVEDD= left 
ventricular end diastolic diameter, MRA = Mineralocorticoids receptor antagonists,  Na+ = sodium, NYHA = New York Heart Association Class, NTproBNP = N-terminal Pro Brain Natriuretic 
Peptide, PNI = Prognostic nutritional Index, PVD = peripheral vascular disease, COPD= chronic obstructive pulmonary disease, HTN= hypertension. 
*P-value for trend except when there are > 2 categories (e.g. NYHA class, cardiac rhythm etc) 
 
Online table 3a: Univariable and multivariable analyses of factors predicting outcomes in patients with CHF with HeFREF. 
Worse outcome per 
unitary increase 
HeFREF ( LVEF <40) 
Univariable Multivariable 
HR(95%CI) Wald Χ2 P-value HR(95%CI) Wald Χ2 P-value 
Age (years) 1.06 (1.05-1.07) 186.3 <0.001 1.05 (1.04-1.06) 79.0 <0.001 
Sex (male vs female) 1.07 (0.90-1.27) 0.6 0.44    
Height (m) 0.10 (0.05-0.21) 35.1 <0.001    
Weight (kg) 0.99 (0.98-0.99) 43.5 <0.001    
BMI (kg/m
2
) 0.97 (0.95-0.98) 19.5 <0.001    
BP systolic (mmHg) 0.99 (0.99-1.00) 8.2 0.004    
BP diastolic (mmHg) 0.98 (0.98-0.99) 46.3 <0.001 0.99 (0.98-0.99) 12.4 <0.001 
HR (bpm) 1.00 (1.00-1.01) 3.4 0.06    
NYHA 
III/IV vs I/II 
1.79 (1.54-2.08) 57.9 <0.001 1.57 (1.33-1.85) 28.9 <0.001 
Hb (g/dL) 0.85 (0.82-0.89) 55.3 <0.001 0.93 (0.87-0.98) 6.7 0.01 
Urea (mmol/L) 1.05 (1.04-1.05) 101.2 <0.001 1.03 (1.01-1.06) 8.0 0.005 
Creatinine (umol/L) 1.00 (1.00-1.00) 32.9 <0.001    
K+ (mmol/L) 0.87 (0.74-1.01) 3.2 0.07    
Na+ (mmol/L) 0.96 (0.94-0.98) 14.1 <0.001    
Lymphocyte  (x10
9
/L) 0.73 (0.65-0.82) 28.9 <0.001    
Albumin (g/L) 0.91 (0.90-0.93) 91.6 <0.001    
Cholesterol (mmol/L) 0.92 (0.87-0.98) 6.1 0.01    
Log NTproBNP (ng/L) 2.87 (2.49-3.32) 208.3 <0.001 2.03 (1.68-2.46) 53.4 <0.001 
Loop diuretic (Y vs N) 1.87 (1.54-2.28) 39.8 <0.001    
MRA (Y vs N) 0.97 (0.82-1.15) 0.1 0.80    
ACEi (Y vs N) 0.88 (0.75-1.04) 2.4 0.13    
ARB (Y vs N) 1.04 (0.80-1.35) 0.1 0.77    
ACEi or ARB (Y vs N) 0.86 (0.72-1.04) 2.4 0.12    
BB (Y vs N) 0.69 (0.59-0.80) 23.5 <0.001    
Statin (Y vs N) 0.88 (0.76-1.03) 2.7 0.10    
Digoxin (Y vs N) 1.22 (1.01-1.48) 4.2 0.04    
Cardiac rhythm 
AF vs Sinus 
1.39 (1.17-1.66) 13.4 <0.001    
EF (%) 0.97 (0.96-0.99) 17.0 <0.001    
LVEDD (cm) 0.95 (0.87-1.05) 1.0 0.31    
CVA (Y vs N) 1.36 (1.06-1.75) 5.8 0.02    
IHD (Y vs N) 1.36 (1.15-1.60) 13.3 <0.001 1.30 (1.09-1.54) 8.3 0.004 
PVD (Y vs N) 1.90 (1.46-2.49) 22.3 <0.001 2.00 (1.50-2.66) 22.4 <0.001 
Diabetes (Y vs N) 1.14 (0.96-1.36) 2.1 0.15    
Reduced mobility (Y vs N) 2.30 (1.93-2.73) 89.7 <0.001    
Prevalence of malnutrition 
 
CONUT 
Normal 
Mild malnutrition 
Moderate malnutrition 
Severe malnutrition 
 
 
 
1 
1.53 (1.31-1.80) 
2.45 (1.94-3.09) 
4.87 (2.40-9.85) 
 
 
 
- 
27.1 
57.1 
19.4 
 
 
 
- 
<0.001 
<0.001 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
GNRI 
Normal 
Mild malnutrition 
Moderate malnutrition 
Severe malnutrition 
 
 
PNI 
Normal 
Moderate malnutrition 
Severe malnutrition 
 
 
1 
1.51 (1.20-1.90) 
2.40 (1.81-3.18) 
8.17 (5.17-12.92) 
 
 
 
1 
2.31 (1.68-3.16) 
2.20 (1.55-3.13) 
 
- 
12.5 
37.4 
80.9 
 
 
 
- 
26.8 
19.5 
 
- 
<0.001 
<0.001 
<0.001 
 
 
 
- 
<0.001 
<0.001 
 
1.29 (1.13-1.46) 
 
15.2 
 
<0.001 
Online table 3b: Univariable and multivariable analyses of factors predicting outcomes in patients with HF with HeFNEF (LVEF >40  or mild/ 
mild-moderate left ventricular systolic dysfunction and NTProBNP >125ng/L.) 
 
Worse outcome per 
unitary increase 
HeFNEF 
Univariable Multivariable 
HR(95%CI) Wald Χ2 P-value HR(95%CI) Wald Χ2 P-value 
Age (years) 1.06 (1.05-1.07) 223.2 <0.001 1.05 (1.04-1.06) 109.4 <0.001 
Sex (male vs female) 1.22 (1.08-1.39) 1.2 0.001 1.46 (1.26-1.68) 26.6 <0.001 
Height (m) 0.32 (0.18-0.57) 14.8 <0.001    
Weight (kg) 0.99 (0.98-0.99) 30.4 <0.001    
BMI (kg/m
2
) 0.98 (0.97-0.99) 18.0 <0.001    
BP systolic (mmHg) 1.00 (0.99-1.00) 14.9 <0.001    
BP diastolic (mmHg) 0.98 (0.98-0.99) 74.8 <0.001 0.99 (0.99-1.00) 4.0 0.05 
HR (bpm) 1.01 (1.00-1.01) 18.2 <0.001 1.01 (1.00-1.01) 7.8 0.005 
NYHA 
III/IV vs I/II 
2.15 (1.89-2.45) 134.6 <0.001 1.33 (1.07-1.66) 6.6 0.01 
Hb (g/dL) 0.80 (0.77-0.83) 158.3 <0.001 0.93 (0.89-0.97) 9.8 0.002 
Urea (mmol/L) 1.06 (1.06-1.07) 241.2 <0.001    
Creatinine (umol/L) 1.00 (1.00-1.01) 196.1 <0.001 1.00 (1.00-1.00) 7.9 0.005 
K+ (mmol/L) 1.09 (0.96-1.25) 1.7 0.19    
Na+ (mmol/L) 0.93 (0.91-0.95) 62.9 <0.001 0.97 (0.96-0.99) 6.7 0.01 
Lymphocyte  (x10
9
/L) 0.64 (0.57-0.71) 71.2 <0.001    
Albumin (g/L) 0.88 (0.87-0.90) 251.7 <0.001    
Cholesterol (mmol/L) 0.95 (0.90-1.00) 4.7 0.03    
Log NTproBNP (ng/L) 3.06 (2.70-3.47) 303.8 <0.001 1.74 (1.47-2.05) 41.1 <0.001 
Loop diuretic (Y vs N) 2.20 (1.93-2.52) 131.2 <0.001    
MRA (Y vs N) 1.42 (1.19-1.70) 14.8 <0.001    
ACEi (Y vs N) 1.06 (0.93-1.20) 0.7 0.39    
ARB (Y vs N) 0.82 (0.67-1.01) 3.5 0.06    
ACEi or ARB (Y vs N) 1.00 (0.88-1.13) 0.005 0.94    
BB (Y vs N) 0.68 (0.60-0.77) 37.8 <0.001    
Statin (Y vs N) 0.68 (0.60-0.77) 35.5 <0.001    
Digoxin (Y vs N) 1.58 (1.36-1.83) 36.0 <0.001    
Cardiac rhythm 
AF vs Sinus 
1.33 (1.17-1.53) 17.4 <0.001 1.23 (1.04-1.46) 5.9 0.02 
EF (%) 0.98 (0.97-0.99) 12.2 0.51    
LVEDD (cm) 1.01 (0.93-1.10) 0.04 0.84    
CVA (Y vs N) 1.67 (1.34-2.08) 20.7 <0.001 1.40 (1.10-1.78) 7.7 0.006 
IHD (Y vs N) 0.92 (0.81-1.05) 1.6 0.20 0.85 (0.74-0.98) 4.8 0.03 
PVD (Y vs N) 1.62 (1.20-2.17) 10.1 0.001 1.45 (1.06-1.98) 5.4 0.02 
Diabetes (Y vs N) 1.11 (0.96-1.30) 1.9 0.16    
Reduced mobility (Y vs N) 2.03 (1.76-2.35) 91.7 <0.001    
Prevalence of malnutrition 
 
CONUT 
Normal 
Mild malnutrition 
Moderate malnutrition 
Severe malnutrition 
 
 
1 
1.62 (1.42-1.85) 
3.35 (2.74-4.10) 
22.0 (11.70-
 
 
- 
50.2 
137.7 
92.1 
 
 
- 
<0.001 
<0.001 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACEi = Angiotensin-converting enzyme inhibitor, AF= atrial fibrillation, ARB = Angiotensin receptor blocker, BB= betablocker, BMI= body mass index, BP= blood pressure, CONUT = 
Controlling nutritional status, CVA = cerebrovascular disease, ECG= electrocardiogram. EF= ejection fraction,  GNRI = Geriatric nutritional risk index, Hb = Haemoglobin, HF= heart failure, 
HeFREF = heart failure with reduced ejection fraction, HeFNEF = heart failure with normal ejection fraction, HR= heart rate, IHD = ischaemic heart disease, K+ = potassium, LVEDD= left 
ventricular end diastolic diameter, MRA = Mineralocorticoids receptor antagonists,  Na+ = sodium, NYHA = New York Heart Association Class, NTproBNP = N-terminal Pro Brain Natriuretic 
Peptide, PNI = Prognostic nutritional Index, PVD = peripheral vascular disease,Y = yes, N=no.  
 
 
 
GNRI 
Normal 
Mild malnutrition 
Moderate malnutrition 
Severe malnutrition 
 
 
PNI 
Normal 
Moderate malnutrition 
Severe malnutrition 
 
41.50) 
 
1 
1.86 (1.53-2.27) 
2.86 (2.25-3.64) 
5.02 (3.25-7.75) 
 
 
 
1 
3.06 (2.38-3.94) 
3.69 (2.79-4.87) 
 
 
- 
38.7 
72.5 
52.9 
 
 
 
- 
75.5 
84.4 
 
 
- 
<0.001 
<0.001 
<0.001 
 
 
 
- 
<0.001 
<0.001 
 
 
1.18 (1.05-1.33) 
 
 
7.4 
 
 
<0.001 
Online table 4.  Crossvalidation (x) for all patients with chronic heart failure. Crossvalidation (z) for patients chronic heart failure with baseline 
treatment excluded.   
 
 
Baseline variable 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 N % 
Age (years) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
Sex (female vs male) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
BMI (kg/m2)                          0 
0 
0 
0 
BP systolic (mmHg)                          0 
0 
0 
0 
BP diastolic (mmHg) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
HR (bpm)  
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
  
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
0 
24 
0 
96 
NYHA X X X X X X X X X X X X X X X X X X X X X X X X X 25 100 
III/IV vs I/II Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z 25 100 
Hb (g/dL)      
Z 
      
 
              0 
1 
0 
4 
Urea (mmol/L) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
Creatinine (umol/L)  
Z 
   
 
          X  X    
Z 
     2 
2 
8 
8 
K+ (mmol/L)                          0 
0 
0 
0 
Na+ (mmol/L)   
Z 
X  
Z 
 
Z 
 
Z 
  X   X 
Z 
X 
Z 
X 
Z 
 X 
Z 
    
Z 
 
Z 
 
Z 
X  
Z 
 7 
12 
28 
48 
Lymphocyte  (x109/L)  
Z 
 
Z 
 
 
 
 
 
 
       X X   
Z 
         2 
3 
8 
12 
Albumin (g/L) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
10 
Cholesterol (mmol/L)  
Z 
 
Z 
 
 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
 
Z 
  
Z 
 
Z 
 
Z 
 
Z 
 
Z 
0 
23 
0 
92 
 Log NTproBNP (ng/L) X 
Z 
X 
Z 
X 
Z 
 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
Loop diuretic (Y vs N) X X X X X X X X X X X X X X X X X X X X X X X X X 25 100 
MRA (Y vs N)                          0 0 
ACEi or ARB (Y vs N)                          0 0 
BB (Y vs N) X X X X X X X X X X X X X X X X X X X X X X X X X 25 100 
Statin (Y vs N) X X x X   X X X X X    X X   X X X  X X  11 44 
Digoxin (Y vs N) X X   X X X X X X X X X X X X  X X X  X X X X 21 84 
Cardiac rhythm 
AF vs Sinus 
                         0 
0 
0 
0 
LVEDD (cm)                          0 
0 
0 
0 
CVA (Y vs N) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
IHD (Y vs N) X X X X X X X X X X X X X X X X X X X X X X X X X 25 100 
0 0 
PVD (Y vs N) X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
CONUT 
category 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
GNRI category 
 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
25 
25 
100 
100 
PNI 
category 
X 
Z 
X 
Z 
 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
X 
Z 
 
Z 
 
Z 
 
Z 
X  
 
X X 
Z 
X X 
Z 
19 
20 
76 
80 
#deaths all-cause 1
2
9
4 
1
3
1
5 
1
2
9
5 
1
3
1
1 
1
3
0
4 
1
3
0
5 
1
3
0
2 
1
3
0
3 
1
3
0
3 
1
3
0
9 
1
2
9
6 
1
3
1
8 
1
3
0
4 
1
3
1
7 
1
2
8
7 
1
3
1
8 
1
2
8
6 
1
3
0
8 
130
3 
131
8 
128
8 
130
2 
129
6 
130
1 
130
2 
131
8 
130
2 
130
3 
129
8 
131
0 
129
0 
131
7 
128
6 
131
6 
129
5 
131
2 
129
9 
131
2 
129
5 
130
0 
129
8 
130
9 
130
5 
131
4 
 
129
5 
131
0 
130
3 
131
2 
129
9 
131
9 
 
 
 
 
ACEi = Angiotensin-converting enzyme inhibitor, ARB = Angiotensin receptor blocker, AF= atrial fibrillation, BB= betablocker, BMI= body mass index, BP= blood pressure, CONUT = 
Controlling nutritional status, CVA = cerebrovascular disease, EF= ejection fraction, GNRI = Geriatric nutritional risk index, Hb = Haemoglobin, HR= heart rate, IHD = ischaemic heart 
disease, K+ = potassium, LVEDD= left ventricular end diastolic diameter, MRA = Mineralocorticoids receptor antagonists, Na+ = sodium, NTProBNP = N-terminal Pro Brain Natriuretic 
Peptide, NYHA = New York Heart Association Class, PNI = Prognostic nutritional Index,  PVD = peripheral vascular disease. 
 
Online table 5: Summary of findings from other studies which reported the role of 
malnutrition scores in predicting outcomes using different risk models. 
Study Number of 
patients 
Outcome Malnutrition tool Country Findings 
Narumi et al
i
  
(2013) 
388 patients 
with stable 
CHF 
Cardiovascular 
death  
GNRI, CONUT, PNI Japan MV model including age, 
gender, NYHA and BNP 
 
Severe CONUT score (HR 
9.4), severe PNI score (HR 
3.8) and severe GNRI score 
(HR 6.0) predicted 
cardiovascular events in MV 
analysis (all p <0.001). 
Kaneko et al
ii
  
(2014) 
438 patients 
with 
decompensated 
HF 
All-cause 
mortality, HF 
hospitalisation, 
composite 
mortality and 
HF 
hospitalisation  
GNRI Japan MV model including 
age ≥ 75 years, male gender, 
CKD, DCM, RAS-I, 
BNP≥ 1000 pg/mL, 
LVDd ≥ 55 mm. Lower 
GNRI (per unitary decrease) 
predicted all-cause mortality 
(UV: HR=2.2, p=0.004; 
MV: HR=2.0, p=0.009), HF 
hospitalisation (UV: 
HR=1.6, p=0.03; MV: 
HR=1.8, p=0.01), and 
composite endpoint (UV: 
HR=1.9, p=0.001; MV: 
HR=1.9, p=0.001),  in both 
UV and MV analysis. 
 
Kinugasa et al
iii
 
(2013) 
152 patients 
with 
decompensated 
HFNEF 
All-cause 
mortality 
GNRI Japan 
 
MV model including age, 
sex, BNP and BUN, prior 
HF hospitalisation, Na, 
eGFR. BMI excluded as in 
GNRI. Lower GNRI (per 
unitary decrease) predicted 
increased mortality in UV 
(HR 0.95, p<0.001) and MV 
(HR 0.95, p<0.001) 
analysis. 
AUC of risk model (GNRI+ 
age+gender) was 
significantly higher 
compared to that of (BMI+ 
age+ gender). (AUC 0.75 
(p= 0.049) vs 0.70 
(reference)) 
Gouya et al
iv
 
(2014) 
137 patients 
with stable 
chronic HF 
All-cause 
mortality 
HF 
hospitalisation 
NRI (patients grouped 
into 2 NRI groups (< 
or ≥ cut off) according 
to cut off point 
calculated based on 
ROC analysis to 
provide the greatest 
sum of sensitivity and 
specificity for 
mortality) 
Austria MV model including age, 
waist circumference, LVEF, 
SBP, ghrelin, adiponectin 
and the NRI (categorical 
variable), after adjusting for 
NTproBNP, NRI (HR = 2.4, 
p = 0.37) and waist 
circumference (HR = 1.1; 
p = 0.004) were significant 
predictors of mortality but 
not of HF hospitalisations.  
Aziz et al
v
  
(2011) 
1110 patients 
with 
decompensated 
HF 
Composite 
endpoint of 
all-cause 
mortality and 
HF 
hospitalisation 
NRI USA MV model including age, 
BMI, NRI, eGFR, CAD 
NRI (per unitary decrease) 
was the most significant 
predictor of outcome in both 
UV (HR 3.03, p<0.0001) 
and MV models (HR 3.1, 
p<0.0001). 
BMI was a significant 
predictor of outcome in UV 
model (HR 0.96; p<0001) 
but was insignificant in MV 
analysis (HR 1; p = 0.69). 
Al-Najjar et al
vi
 
(2012) 
538 patients 
with stable 
chronic HF 
All-cause 
mortality 
NRI UK BMI was not a significant 
predictor of outcome in UV 
analysis (HR 0.98, p=0.31).  
BMI not included in MV 
models (Age, urea, creat, 
LVF, WCC, NRI, Albumin, 
Hb, Na) as it is part of NRI 
score.  
NRI (per unitary increase) 
was a significant predictor 
of outcome both UV (HR 
0.98, p<0.001 & MV 
analyses (HR 0.95, 
p<0.001).  
 
MV= multivariable, UV= univariable, NRI = nutritional risk index (NRI = (1.519 × serum 
albumin, g/dL) ,+ {41.7 × present weight (kg)/ideal body weight(kg), GNRI= geriatric 
nutritional risk index, PNI= prognostic nutritional index, CONUT= controlling nutritional status 
score, NYHA = New York Association functional class, eGFR = estimated glomerular 
filtration rate, CAD= coronary artery disease, LVEF= left ventricular ejection fraction,  WCC= 
white cell count, Hb= haemoglobin, Na = sodium, LVF= left ventricular function, HFNEF= 
heart failure with normal ejection fraction, BUN= blood urea nitrogen, AUC = area under 
curve, CKD = chronic kidney disease, DCM = dilated caradiomyopathy, RAS-I = renin-
angiotensin system inhibitor, BNP= brain natriuretic peptide, LVDd = left ventricular diastolic 
dimension. 
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